PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York.\', \'Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.\', \'Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.\', \'Department of Cardiology, Lenox Hill Hospital, Northwell Health, New York, New York.\', \'Department of Medicine, Newark Beth Israel Medical Center, Newark, New Jersey.\', \'WellSpan York Hospital, York, Pennsylvania.\', \'Department of Medicine, Cardiovascular Institute, NorthShore University HealthSystem, Evanston, Illinois.\', \'Division of Cardiology, Pritzker School of Medicine, University of Chicago, Chicago, Illinois.\', \'BayCare Health System, Inc, Clearwater, Florida.\', \'Division of Cardiovascular Medicine, Department of Medicine, Froedtert & the Medical College of Wisconsin, Milwaukee.\', \'Biostatistics Unit, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York.\', \'Colorado Prevention Center (CPC) Clinical Research, Aurora.\', \'Division of Cardiology, University of Colorado School of Medicine, University of Colorado, Aurora.\', \'Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, New York.\', \'Department of Medicine, McMaster University, Hamilton, Ontario, Canada.\', \'Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.\', \'Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1001/jamainternmed.2021.6203
?:doi
?:hasPublicationType
?:journal
  • JAMA internal medicine
is ?:pmid of
?:pmid
?:pmid
  • 34617959
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 8.032
?:rankingScore_hIndex
  • 300
is ?:relation_isRelatedTo_publication of
?:title
  • Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34617959>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34617959>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all